Cite
HARVARD Citation
Jerusalem, G. et al. (n.d.). 331PRibociclib (RIB) + fulvestrant (FUL) for advanced breast cancer (ABC): Progression-free survival (PFS) subgroup and tumor response analyses from MONALEESA-3. Annals of oncology. p. . [Online].